Confronto
LL-37 vs. Pasireotid
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
597562-32-8
396091-73-9
Peso molecolare
4493.33 g/mol
1047.21 g/mol
Emivita
nessun dato
nessun dato
Sequenza
LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTESnessun dato
Meccanismo d'azione
LL-37
LL-37 is a cationic, amphipathic helical peptide and the only member of the cathelicidin family in humans. It is generated by proteolytic cleavage from the C-terminal portion of the precursor protein hCAP18 (CAP-18). Mechanistically it associates with and can permeabilize microbial membranes; in addition it modulates immune cells, influences cytokine release, exerts chemotactic activity, and can bind extracellular self-DNA. Preclinical models have described both anti-inflammatory and pro-inflammatory effects, depending on concentration and tissue context.
Pasireotid
Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.
Base di evidenze
Evidenza più alta
Studio sull'uomo
RCT sull'uomo
Studi
4
1
di cui sull'uomo
1
1
Effetti registrati
4
2
Contraddizioni aperte
1
0
Eventi avversi documentati
0
2
Stato legale
Voci complete
Frequently asked questions
- What is the difference between LL-37 and Pasireotid?
- LL-37 is classified as "Ricerca (altro)", while Pasireotid is classified as "Ricerca (altro)". LL-37: LL-37 is the only known human cathelicidin, a 37-amino-acid antimicrobial peptide generated by cleavage of the precursor protein hCAP18. In research it plays a central role in innate immune defence and wound healing, yet acts in a context-dependent manner as both anti- and pro-inflammatory and has been linked to autoimmune processes. LL-37 is not an approved drug; the evidence base is predominantly basic and preclinical. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, LL-37 or Pasireotid?
- The highest available evidence level is "Studio sull'uomo" for LL-37 and "RCT sull'uomo" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of LL-37 and Pasireotid in Germany and the United States?
- Germania: LL-37 — Solo ricerca, Pasireotid — Su prescrizione. Stati Uniti: LL-37 — Solo ricerca, Pasireotid — Su prescrizione. These are factual summaries with source and review date on the individual pages.